FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 342:975-976 March 30, 2000 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Raje, N. Related Article by Singhal, S. PubMed Citation

To the Editor: Singhal et al. (Nov. 18 issue)¹ report the results of a phase 2 study of thalidomide for the treatment of multiple myeloma and conclude that the drug can reduce serum and urine levels of paraprotein in some patients with refractory multiple myeloma. We are concerned that the maximal tolerated dose of thalidomide was not clarified in this study.

Thalidomide was started at a dose of 200 mg per day, and the dose was increased by 200 mg every two weeks, until a dose of 800 mg per day was reached. It is surprising that only 55 percent . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Antoniou, K. M., Ferdoutsis, E., Bouros, D. (2003). Interferons and Their Application in the Diseases of the Lung. Chest 123: 209-216 [Abstract] [Full Text]  
• Grad, J. M., Bahlis, N. J., Reis, I., Oshiro, M. M., Dalton, W. S., Boise, L. H. (2001). Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 98: 805-813 [Abstract] [Full Text]